CA2227442A1 - 4,5-diaryl oxazole derivatives - Google Patents

4,5-diaryl oxazole derivatives Download PDF

Info

Publication number
CA2227442A1
CA2227442A1 CA002227442A CA2227442A CA2227442A1 CA 2227442 A1 CA2227442 A1 CA 2227442A1 CA 002227442 A CA002227442 A CA 002227442A CA 2227442 A CA2227442 A CA 2227442A CA 2227442 A1 CA2227442 A1 CA 2227442A1
Authority
CA
Canada
Prior art keywords
compound
diphenyloxazol
salt
nmr
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002227442A
Other languages
English (en)
French (fr)
Inventor
Kiyoshi Taniguchi
Kouji Hattori
Kazunori Tsubaki
Osamu Okitsu
Seiichiro Tabuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515085.0A external-priority patent/GB9515085D0/en
Priority claimed from AUPN9002A external-priority patent/AUPN900296A0/en
Application filed by Individual filed Critical Individual
Publication of CA2227442A1 publication Critical patent/CA2227442A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002227442A 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives Abandoned CA2227442A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9515085.0A GB9515085D0 (en) 1995-07-21 1995-07-21 Heterocyclic compounds
GB9515085.0 1995-07-21
AUPN9002 1996-03-29
AUPN9002A AUPN900296A0 (en) 1996-03-29 1996-03-29 Heterocyclic compounds
PCT/JP1996/001996 WO1997003973A1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives

Publications (1)

Publication Number Publication Date
CA2227442A1 true CA2227442A1 (en) 1997-02-06

Family

ID=25645150

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002227442A Abandoned CA2227442A1 (en) 1995-07-21 1996-07-18 4,5-diaryl oxazole derivatives

Country Status (17)

Country Link
US (2) US5972965A (zh)
EP (2) EP1213285A3 (zh)
JP (1) JPH11509191A (zh)
KR (1) KR19990063582A (zh)
CN (1) CN1095839C (zh)
AT (1) ATE224380T1 (zh)
AU (1) AU716304B2 (zh)
CA (1) CA2227442A1 (zh)
DE (1) DE69623785T2 (zh)
DK (1) DK0842161T3 (zh)
EA (1) EA002156B1 (zh)
ES (1) ES2181902T3 (zh)
HU (1) HUP9900881A3 (zh)
MX (1) MX9800577A (zh)
PT (1) PT842161E (zh)
TW (1) TW401408B (zh)
WO (1) WO1997003973A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO713297A0 (en) * 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AUPP003297A0 (en) 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
DE19801648A1 (de) * 1998-01-17 1999-07-22 Bayer Ag alpha-Substituierte Lactone
GB9804426D0 (en) 1998-03-02 1998-04-29 Pfizer Ltd Heterocycles
AUPP608898A0 (en) * 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) * 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
EP1159266B1 (en) 1999-03-05 2004-11-03 Duke University C-16 unsaturated fp-selective prostaglandins analogs
AU5249200A (en) * 1999-06-21 2001-01-09 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
US6894175B1 (en) * 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AUPQ253199A0 (en) * 1999-08-30 1999-09-23 Fujisawa Pharmaceutical Co., Ltd. Non-prostanoid prostaglandin I2-agonist
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
WO2002085412A1 (fr) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la fibrose des tissus
IL158491A0 (en) 2001-04-19 2004-05-12 Eisai Co Ltd 2-iminopyrrolidine derivatives
RU2306309C2 (ru) * 2002-03-05 2007-09-20 Оно Фармасьютикал Ко., Лтд. Производное 8-азапростагландина, фармацевтическая композиция, агент для профилактики заболеваний
IL164263A0 (en) * 2002-04-12 2005-12-18 Pfizer Use of ep4 receptor ligands on the treatment of il-6 involved diseases
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
CA2515119A1 (en) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivative
JP4549970B2 (ja) 2003-02-19 2010-09-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 環状ベンズアミジン誘導体の製造方法
US7557095B2 (en) 2006-05-12 2009-07-07 Allergan, Inc. Therapeutic compounds
MY163762A (en) 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure
RU2509768C2 (ru) 2008-09-10 2014-03-20 Асахи Гласс Компани, Лимитед Новое производное простагландина i2
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
PT2545917T (pt) * 2010-03-08 2016-10-25 Kaken Pharma Co Ltd Novo agonista de ep4
EP2606044B1 (en) * 2010-08-20 2014-06-04 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US9018380B2 (en) * 2012-08-24 2015-04-28 Boar of Regents, The University of Texas System Heterocyclic modulators of HIF activity for treatment of disease
WO2014031933A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
WO2014031928A2 (en) * 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
ES2726648T3 (es) 2014-02-25 2019-10-08 Univ Texas Sales de moduladores heterocíclicos de la actividad del HIF para el tratamiento de enfermedades

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ236474A (en) * 1989-12-20 1993-07-27 Bristol Myers Squibb Co 4,5-diphenyl-2-oxazole octanoic, nonanoic and decanoic acid and ester derivatives, preparation and pharmaceutical compositions thereof
US5348969A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Diphenyloxazolyl-oxazoles as platelet aggregation inhibitors
US5187188A (en) * 1992-04-03 1993-02-16 Bristol-Myers Squibb Company Oxazole carboxylic acid derivatives
US5362879A (en) * 1993-04-15 1994-11-08 Bristol-Myers Squibb Company 4-5-diphenyloxazole derivatives as inhibitors of blood platelet aggregation
RU2176640C2 (ru) * 1993-12-20 2001-12-10 Фудзисава Фармасьютикал Ко., Лтд. Гетероциклические соединения или их фармацевтически приемлемая соль, промежуточные соединения
TW282456B (zh) 1994-03-10 1996-08-01 Fujisawa Yakusin Kogyo Kk

Also Published As

Publication number Publication date
HUP9900881A2 (hu) 1999-08-30
EP1213285A3 (en) 2002-07-03
EP0842161B1 (en) 2002-09-18
AU716304B2 (en) 2000-02-24
KR19990063582A (ko) 1999-07-26
JPH11509191A (ja) 1999-08-17
MX9800577A (es) 1998-04-30
TW401408B (en) 2000-08-11
CN1095839C (zh) 2002-12-11
DK0842161T3 (da) 2003-01-27
CN1196726A (zh) 1998-10-21
HUP9900881A3 (en) 2000-09-28
EA002156B1 (ru) 2001-12-24
DE69623785T2 (de) 2003-08-07
WO1997003973A1 (en) 1997-02-06
EA199800141A1 (ru) 1998-08-27
EP0842161A1 (en) 1998-05-20
US6300344B1 (en) 2001-10-09
DE69623785D1 (de) 2002-10-24
EP1213285A2 (en) 2002-06-12
PT842161E (pt) 2003-02-28
ATE224380T1 (de) 2002-10-15
AU6469796A (en) 1997-02-18
US5972965A (en) 1999-10-26
ES2181902T3 (es) 2003-03-01

Similar Documents

Publication Publication Date Title
CA2227442A1 (en) 4,5-diaryl oxazole derivatives
EP0736018B1 (en) 4,5-diaryloxazole derivatives
US5763489A (en) Naphthalene derivatives as prostaglandin I2 agonsists
IL180432A (en) CETP inhibitors
US6660759B1 (en) 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity
BG98689A (bg) Хетероарилни амини като нови ацетилхолинестеразни инхибитори
JPH02134380A (ja) 新規化合物、その製法及びそれを含む医薬組成物
JP2006525990A (ja) 神経変性障害の処置のためのイソオキサゾール化合物およびイソチアゾール化合物
CA2697166A1 (en) Isophthalamide derivatives inhibiting betasecretase activity
ES2198778T3 (es) Derivados de naftaleno.
US6384072B1 (en) Benzocycloheptene derivatives
US6297267B1 (en) 4,5-diaryloxazole compounds
JP2001163862A (ja) テトラヒドロピリダジン誘導体
JP2009520719A (ja) 置換された三環状ピペリドン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued